Brian Biesman, M.D., FACS

Dr. Brian S. Biesman specializes in cosmetic and reconstructive eyelid and facial surgery, as well as minimally invasive rejuvenation techniques, including injectables (neuromodulators, soft tissue fillers, and biostimulators), energy-based devices, and topical agents. Dr. Biesman is an internationally recognized authority in facial aesthetics and serves as a Clinical Associate Professor at Vanderbilt University Medical Center in Nashville, TN, where he holds appointments in the divisions of Ophthalmology, Dermatology, and Otolaryngology–Head and Neck Surgery.
Financial relationships
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:AcclaroTopic:AestheticsDate added:06/12/2026Date updated:06/12/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:AbbvieTopic:AestheticsDate added:06/12/2026Date updated:06/12/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:BotanixTopic:AestheticsDate added:06/12/2026Date updated:06/12/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:CanfieldTopic:AestheticsDate added:06/12/2026Date updated:06/12/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:GaldermaTopic:AestheticsDate added:06/12/2026Date updated:06/12/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:HugelTopic:AestheticsDate added:06/12/2026Date updated:06/12/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:La MerTopic:AestheticsDate added:06/12/2026Date updated:06/12/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:LOrealTopic:AestheticsDate added:06/12/2026Date updated:06/12/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:LRMTopic:AestheticsDate added:06/12/2026Date updated:06/12/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:MerzTopic:AestheticsDate added:06/12/2026Date updated:06/12/2026

Facebook
X
LinkedIn
Forward